MARKET

SNY

SNY

Sanofi FR
NASDAQ
43.50
-0.40
-0.91%
After Hours: 43.57 +0.07 +0.16% 18:26 07/10 EDT
OPEN
43.49
PREV CLOSE
43.90
HIGH
43.68
LOW
43.24
VOLUME
2.66M
TURNOVER
--
52 WEEK HIGH
49.91
52 WEEK LOW
40.89
MARKET CAP
105.06B
P/E (TTM)
20.71
1D
5D
1M
3M
1Y
5Y
1D
Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug
Benzinga · 1d ago
Analysts Conflicted on These Healthcare Names: Sanofi (SNY) and Johnson & Johnson (JNJ)
TipRanks · 1d ago
Sanofi reports 1,214,099,027 shares outstanding as of June 30, 2026
PUBT · 1d ago
Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector
NASDAQ · 1d ago
Sanofi wins FDA nod for injectable multiple myeloma therapy
Seeking Alpha · 1d ago
Sanofi's Subcutaneous Sarclisa Escena Receives FDA Approval To Treat Multiple Myeloma
Benzinga · 1d ago
Sanofi announces subcutaneous Sarclisa Escena approved in U.S.
TipRanks · 1d ago
BRIEF-Sanofi: Subcutaneous Sarclisa Escena Approved In US
Reuters · 1d ago
More
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.